3D Medicines Inc. (HKG:1244)

Market Cap	660.30M -57.4%
Revenue (ttm)	412.66M -20.3%
Net Income	-200.20M
EPS	-0.81
Shares Out	245.92M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	22,000
Open	2.680
Previous Close	2.690
Day's Range	2.680 - 2.690
52-Week Range	1.820 - 6.280
Beta	0.15
Analysts	n/a
Price Target	n/a
Est. Earnings	Dec 1, 2026

About 3D Medicines

3D Medicines Inc., a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products in the People’s Republic of China. The company offers Envafolimab, a PD-L1 antibody in the form of subcutaneous injection for the treatment of previously treated microsatellite instability-high (MSI-H)/mismatch repair deficient(dMMR) advanced solid tumors. It is also developing Envafolimab, which is in Phase III clinical trials for advanced BTC and NSCLC, and TMB-H advanced cancer; and in Phase II clinical trial...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 162
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 1244

Financial Performance

In 2025, 3D Medicines's revenue was 356.09 million, a decrease of -20.10% compared to the previous year's 445.65 million. Losses were -177.53 million, -2.81% less than in 2024.

Financial numbers in CNY

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 3, 2026

Data Sources Report a data error